PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY.
Eur J Pharmacol. 2008 Oct 24;595(1-3):119-25. Epub 2008 Aug 12.PMID: 18727927 [PubMed - indexed for MEDLINE]Related articles